Retrospective analysis indicated markedly better clinical outcomes in patients who received chemotherapy, suggesting that specific mutations in TP53, especially at codon 273, could be critical in determining the effectiveness of therapy in astrocytomas and, consequently, in affecting survival rates. The gene discussed is TP53; the disease is astrocytoma (excluding glioblastoma).